Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.75 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811531 | 1.00 | BACE1 (0.75) | BACE1PTGS2NPC1RAB9ALMNA | |
| SCHEMBL4806389 | 0.89 | BACE1 (0.75) | BACE1PTGS2 | |
| SCHEMBL5915604 | 0.86 | BACE1 (1.00) | BACE1NPC1RAB9A | |
| SCHEMBL4807197 | 0.86 | BACE1 (1.00) | BACE1NPC1RAB9A | |
| SCHEMBL5915918 | 0.84 | BACE1 (0.69) | BACE1NPC1RAB9AHDAC8 | |
| SCHEMBL4805204 | 0.84 | BACE1 (0.69) | BACE1NPC1RAB9AHDAC8 | |
| SCHEMBL4813807 | 0.84 | BACE1 (0.54) | BACE1PTGS2LMNAL3MBTL1KMT2A | |
| SCHEMBL4811686 | 0.84 | BACE1 (0.55) | BACE1 | |
| SCHEMBL4811801 | 0.83 | BACE1 (0.55) | BACE1PTGS2 | |
| SCHEMBL4813819 | 0.83 | BACE1 (0.67) | BACE1NPC1RAB9ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459567-B2 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| WO-2006088694-A1 | SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | BACE1, BACE2, PSEN1 | BACE1 1/4885PTGS2 1433/4885NPC1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.